Lakefront Biotherapeutics NV current report, Q2 FY2021

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of June 2021, specifically dated June 22, 2021. The filing serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. It is a procedural filing to distribute a press release and does not include revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The filing text does not detail specific material changes or comparative period analysis. It solely references the issuance of a press release on June 22, 2021, which is attached as Exhibit 99.1.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that the press release (Exhibit 99.1) is incorporated by reference into various Registration Statements (Forms F-3 and S-8), but the content of that press release is not included in the provided text.

Key Facts for Investor Verification

  • Verify the content of Exhibit 99.1 (Press Release dated June 22, 2021) to understand the material event triggering this filing.
  • Confirm the registrant is Galapagos NV, as the metadata company name "Lakefront Biotherapeutics NV" appears to be incorrect based on the filing text.
  • Note that this document is a Form 6-K for a foreign private issuer, meaning detailed financial statements are likely found in the referenced annual reports (Form 20-F) rather than this specific filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.